Disc Medicine (IRON) Is Up 7.2% After Advancing Bitopertin Phase 3 Despite FDA Efficacy Concerns
Disc Medicine's stock rose 7.2% after it announced the completion of patient enrollment and dosing in its expanded pivotal Phase 3 APOLLO trial for bitopertin, a drug for erythropoietic and X-linked protoporphyria. This development occurs despite a previous FDA Complete Response Letter citing insufficient efficacy in earlier trials, creating a complex risk-reward profile for the company. The market's reaction reflects a renewed interest in the drug's potential, betting on the success of the Phase 3 data expected in late 2026.
Assessing Disc Medicine (IRON) Valuation After FDA Complete Response Letter And Shareholder Investigation
Disc Medicine (IRON) is under scrutiny after the FDA issued a Complete Response Letter for its bitopertin program, causing a 22% stock drop and triggering a shareholder investigation. Despite some strong longer-term share price gains, the company trades at a Price-to-Book ratio of 3.4x, which is higher than the broader US biotech average. However, a Discounted Cash Flow model suggests the stock is materially undervalued at $65.18, against an estimated fair value of $131.23 per share.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Disc Medicine, Inc. (IRON) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating Disc Medicine, Inc. (IRON) on behalf of investors following a 22% stock drop on February 13, 2026. This decline occurred after the FDA issued a Complete Response Letter for Disc Medicine's bitopertin program, indicating uncertainties in their new drug application. The law firm is encouraging shareholders to connect and assist in the investigation of potential claims.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Disc Medicine, Inc. (IRON) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Disc Medicine, Inc. (IRON) following a 22% stock drop after the FDA issued a Complete Response Letter for its bitopertin drug, citing uncertainties. The firm is encouraging shareholders who purchased Disc Medicine securities to reach out for additional information and to assist in the investigation, offering representation on a contingency fee basis.
ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM,
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter for its bitopertin program, causing a 22% stock price drop. The firm encourages investors who purchased Disc Medicine securities to inquire about the class action investigation, highlighting its track record in investor rights litigation.
ROSEN Law Firm Encourages Disc Medicine Investors - NYC Today
The ROSEN Law Firm is investigating potential securities claims against Disc Medicine, Inc., a biopharmaceutical company. The firm encourages investors who have suffered losses to contact them for potential legal action. This investigation highlights concerns about the company's actions or disclosures and the importance for investors to monitor their holdings.
ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages Disc Medicine, Inc. Investors ...
Rosen Law Firm has announced an investigation into potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) due to allegations of misleading business information. This follows the U.S. Food and Drug Administration issuing a Complete Response Letter to Disc Medicine regarding its bitopertin program, leading to a 32% stock price drop on February 13, 2024. Investors are encouraged to contact Rosen Law Firm to learn more about joining the prospective class action.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRON
Pomerantz LLP is investigating potential claims against Disc Medicine, Inc. (NASDAQ: IRON) on behalf of investors. This investigation follows significant drops in Disc's stock price due to concerns flagged by the FDA regarding a drug under development and a subsequent Complete Response Letter for its New Drug Application for bitopertin. Investors are encouraged to contact the law firm for more information regarding potential securities fraud or unlawful business practices.
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are ...
The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine, Inc. (NASDAQ: IRON) shareholders. This follows allegations that Disc Medicine may have issued misleading business information, particularly after the U.S. FDA issued a Complete Response Letter regarding the company's bitopertin program in February 2026, causing a 22% stock drop. The firm encourages affected investors to contact them to discuss potential recovery of losses through a class action.
Disc Medicine, Inc. (IRON) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased Disc Medicine, Inc. (NASDAQ: IRON) securities. This investigation follows the U.S. Food and Drug Administration's (FDA) issuance of a Complete Response Letter regarding Disc Medicine's bitopertin program, leading to a significant 22% drop in the company's stock price on February 13, 2026. The firm encourages affected investors to contact them to learn more about the investigation and potentially assist in recovering losses.
IRON Investors Lose Up to $22/Share -- LEVI & KORSINSKY, LLP Investigates Disc Medicine
Levi & Korsinsky, LLP is investigating Disc Medicine, Inc. (NASDAQ: IRON) after its stock collapsed by 21.9% following a Complete Response Letter from the FDA. The investigation will focus on whether Disc Medicine and its officers disclosed material information to investors in a timely manner regarding regulatory developments for its bitopertin program. Shareholders who incurred losses due to the stock decline are encouraged to contact the firm for more information.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, ...
Pomerantz LLP is investigating potential securities fraud claims against Disc Medicine, Inc. (NASDAQ: IRON) on behalf of investors. The investigation follows two significant drops in Disc Medicine's stock price after negative news regarding its drug development, including a delay in FDA review and a Complete Response Letter from the FDA for its drug bitopertin due to insufficient trial data.
IRON Investor News: If You Have Suffered Losses in Disc
The Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter regarding its bitopertin program, causing the stock price to fall by 22%. Investors who have suffered losses are encouraged to contact the firm for potential compensation through a class action lawsuit.
IRON Investor News: If You Have Suffered Losses in Disc
The Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) after the company received a Complete Response Letter from the FDA for its bitopertin program. This letter, which stated uncertainties needed additional evidence for approval, led to a 22% drop in Disc Medicine's stock price on February 13, 2026. Shareholders who suffered losses are encouraged to contact the firm regarding a prospective class action lawsuit.
Disc Medicine, Inc. (IRON) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Disc Medicine, Inc. (NASDAQ:IRON) following a 22% stock drop on February 13, 2026. This decline occurred after the FDA issued a Complete Response Letter for Disc Medicine's bitopertin program, citing uncertainties that require additional evidence for approval. The law firm is encouraging shareholders to contact them to learn more about the ongoing investigation.
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter for its bitopertin program, causing a 22% stock drop. Investors who purchased Disc Medicine securities may be entitled to compensation through a class action lawsuit. The firm encourages affected investors to contact them for more information.
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Disc Medicine, Inc. (IRON)
Levi & Korsinsky has initiated an investigation into Disc Medicine, Inc. (NASDAQ: IRON) regarding potential federal securities law violations. This follows the FDA's Complete Response Letter for bitopertin, the company's lead therapeutic candidate, which indicates that the application cannot be approved in its current form and requires additional data, effectively delaying approval until at least 2027. The investigation focuses on whether Disc Medicine's public communications adequately represented the risks associated with the bitopertin program prior to the FDA's decision, which led to a 21.9% decline in the company's shares.
Disc Medicine, Inc. (NASDAQ:IRON) Receives Average Rating of "Moderate Buy" from Brokerages
Disc Medicine, Inc. (NASDAQ:IRON) has received a consensus "Moderate Buy" rating from twelve brokerage firms, with an average 1-year target price of $104.80. Despite this positive sentiment, company insiders have been net sellers, liquidating 54,522 shares worth approximately $3.58 million in the last 90 days. The clinical-stage biotechnology company reported a quarterly EPS of ($1.62) and currently has a market capitalization of $2.29 billion.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Disc Medicine, Inc. (IRON) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating Disc Medicine, Inc. (IRON) following a 22% stock price drop on February 13, 2026. The decline occurred after the FDA issued a Complete Response Letter for Disc Medicine's bitopertin program, citing uncertainties in the new drug application requiring additional evidence. The law firm is encouraging investors who purchased Disc Medicine securities to connect with them for further information and to assist in the investigation.
Expanded Phase 3 APOLLO Enrollment for Bitopertin in EPP/XLP Might Change The Case For Investing In Disc Medicine (IRON)
Disc Medicine (IRON) has completed enrollment for its expanded Phase 3 APOLLO trial of bitopertin for erythropoietic protoporphyria and X-linked protoporphyria, with top-line data expected in Q4 2026 and an FDA decision by mid-2027. This milestone reduces execution risk but increases the importance of the trial's outcome, especially given the company's rising losses, zero revenue, and reliance on a single pivotal program for near-term value. Investors are advised to consider the binary nature of the program and potential outcomes if the APOLLO trial data is not positive.
Bronstein, Gewirtz & Grossman, LLC Encourages Disc Medicine, Inc. (IRON) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is urging stockholders of Disc Medicine, Inc. (NASDAQ: IRON) to contact the firm regarding a securities investigation. This investigation follows a 22% stock price drop on February 13, 2026, after the U.S. FDA issued a Complete Response Letter for Disc Medicine's bitopertin program, citing uncertainties in its new drug application. The law firm is representing investors in potential class actions on a contingency fee basis.
A Look At Disc Medicine (IRON) Valuation As APOLLO Phase 3 Trial Reaches Full Enrollment Milestone
Disc Medicine (IRON) recently completed full enrollment for its pivotal Phase 3 APOLLO study of bitopertin, a significant milestone. While the stock has seen varied short-term performance, it shows a substantial 3-year total shareholder return, and its valuation is attractive based on a discounted cash flow model. However, the company is still pre-revenue and unprofitable, carrying risks associated with clinical trial outcomes and financing.
Disc Medicine, Inc. Investigated by the Portnoy Law Firm
The Portnoy Law Firm has launched an investigation into Disc Medicine, Inc. (NASDAQ: IRON) for potential securities fraud after the company's stock plummeted due to adverse regulatory disclosures concerning its drug candidate, bitopertin. The decline was triggered by the FDA issuing a "Complete Response Letter" for bitopertin's New Drug Application, citing a lack of evidence for its efficacy in treating erythropoietic protoporphyria (EPP), following earlier safety and efficacy concerns raised by FDA scientists. Investors are encouraged to contact the firm for a case evaluation regarding their losses.
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are ...
Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) on behalf of investors who suffered losses. This investigation follows allegations that Disc Medicine may have released misleading business information, particularly after the FDA issued a Complete Response Letter regarding the company's bitopertin program in February 2026, causing a 22% stock price drop. The firm encourages affected investors to contact them to explore participation in a class action seeking to recover losses.
Disc Medicine, Inc. Investigated by the Portnoy Law Firm
The Portnoy Law Firm has launched an investigation into Disc Medicine, Inc. (NASDAQ: IRON) for potential securities fraud. This follows a significant drop in the company's stock price after the FDA issued a Complete Response Letter for its primary drug candidate, bitopertin, citing lack of efficacy evidence. The firm is encouraging affected investors to contact them to discuss their legal options.
Disc Medicine completes enrollment in bitopertin EPP trial By Investing.com
Disc Medicine Inc. has announced the completion of enrollment for its Phase 3 APOLLO trial of bitopertin for erythropoietic protoporphyria (EPP), with results expected in Q4 2026. Despite a recent workforce reduction and a Complete Response Letter from the FDA requiring more data, analysts remain optimistic about the stock's potential. The company's financial position is strong, though its stock displays high volatility.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Disc Medicine, Inc. (IRON) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into Disc Medicine, Inc. (IRON) following a significant 22% stock price drop on February 13, 2026. This decline occurred after the FDA issued a Complete Response Letter for Disc Medicine's bitopertin program, citing uncertainties in the new drug application. Investors who purchased Disc Medicine securities are encouraged to join the investigation.
Disc Medicine Announces Completion Of Enrollment Of Phase 3 Apollo Trial Of Bitopertin In Erythropoietic Protoporphyria
Disc Medicine has announced the completion of enrollment for its Phase 3 Apollo trial of bitopertin, a drug designed to treat Erythropoietic Protoporphyria (EPP). This marks a significant milestone in the development of bitopertin for patients suffering from this rare genetic disorder. The trial aims to evaluate the efficacy and safety of bitopertin in managing the symptoms of EPP.
Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria
Disc Medicine has announced the completion of enrollment for its pivotal Phase 3 APOLLO trial of bitopertin for Erythropoietic Protoporphyria (EPP), with 183 participants randomized and dosed. The study, originally planned for 150 participants, was expanded due to high demand. Results are anticipated in Q4 2026, and the company aims to engage with regulators to bring bitopertin, an investigational GlyT1 inhibitor, to market as a potential disease-modifying therapy for EPP patients.
Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria
Disc Medicine has announced the completion of enrollment for its Phase 3 APOLLO trial of bitopertin for erythropoietic protoporphyria (EPP). The study was expanded to 183 participants due to high demand, and results are anticipated in Q4 2026. Bitopertin, an investigational oral therapy, aims to be the first disease-modifying treatment for erythropoietic porphyrias.
Disc Medicine expands rare disease trial to 183 patients; data due in Q4
Disc Medicine (NASDAQ:IRON) announced the completion of enrollment for its Phase 3 APOLLO trial of bitopertin for erythropoietic protoporphyria (EPP). The study was expanded to 183 participants from an original target of 150 due to high demand and completed enrollment in under a year. Topline data are expected in Q4 2026, with an FDA decision anticipated by mid-2027.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRON
Pomerantz LLP is investigating Disc Medicine, Inc. (NASDAQ: IRON) on behalf of investors regarding potential securities fraud or unlawful business practices. This investigation follows a Reuters report on January 15, 2026, about safety and efficacy concerns raised by the FDA regarding a Disc drug, causing a 7.84% stock drop. A subsequent FDA Complete Response Letter on February 13, 2026, for bitopertin further led to a 21.91% decline in Disc's stock price.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Disc Medicine, Inc. (IRON) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter for its bitopertin program, causing Disc Medicine's stock price to fall by 22%. The firm encourages stockholders to connect to assist with the investigation, which aims to recover investor capital and ensure corporate accountability.
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm announced an investigation into potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter for its bitopertin program, causing the stock to drop 22%. The firm is preparing a class action lawsuit for investors who suffered losses due to allegedly misleading business information from Disc Medicine. Investors are encouraged to contact The Rosen Law Firm to join the prospective class action.
Hudson Bay Capital Management LP Acquires Shares of 102,185 Disc Medicine, Inc. $IRON
Hudson Bay Capital Management LP has acquired a new position of 102,185 shares in Disc Medicine, Inc. (NASDAQ:IRON), valued at approximately $6.75 million. This purchase represents about 0.27% of the company's stock. Other institutional investors have also adjusted their holdings in Disc Medicine, while analysts maintain a "Moderate Buy" rating with an average price target of $104.80.
JPMorgan Chase & Co. Sells 90,737 Shares of Disc Medicine, Inc. $IRON
JPMorgan Chase & Co. reduced its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 10.8%, selling 90,737 shares and retaining 752,879 shares valued at approximately $49.75 million. Other institutional investors adjusted their positions, and insiders including CFO Jean Franchi and William Jacob Savage also sold shares. Despite insider sales, Wall Street analysts maintain a "Moderate Buy" rating with a consensus target price of $104.80 for the clinical-stage biotechnology company.
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following a 22% stock price drop on February 13, 2026. This decline occurred after the FDA issued a Complete Response Letter for Disc Medicine's bitopertin program, citing uncertainties requiring additional evidence. The firm is preparing a class action lawsuit to recover investor losses.
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
The Rosen Law Firm has announced an investigation into potential securities claims on behalf of Disc Medicine, Inc. (NASDAQ: IRON) shareholders. This follows the FDA's Complete Response Letter regarding Disc Medicine's bitopertin program, which led to a 22% drop in the company's stock price on February 13, 2026. The firm is preparing a class action lawsuit to recover investor losses, citing that the company may have issued misleading business information.
Disc Medicine announces public offering of common stock and pre-funded warrants
Disc Medicine has announced a public offering of common stock and pre-funded warrants. This financial move aims to raise capital, likely to fund ongoing operations, research, and development in the biotechnology sector. The offering will be a key event for investors monitoring the company's financial strategy.
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation – IRON
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter regarding its bitopertin program, causing a 22% stock drop. Investors who purchased Disc Medicine securities may be entitled to compensation and are encouraged to join the prospective class action investigation. The firm highlights its track record in securities class actions, urging investors to select experienced counsel.
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation – IRON
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following allegations that the company may have issued misleading business information. This investigation comes after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter to Disc Medicine regarding its bitopertin program, citing uncertainties that require additional evidence for approval. As a result of this news, Disc Medicine's stock price reportedly fell 22% on February 13, 2026.
IRON Drops Up to 39% After FDA CRL for Bitopertin -- LEVI & KORSINSKY, LLP Investigates
Disc Medicine (NASDAQ: IRON) shares dropped significantly after the FDA issued a Complete Response Letter (CRL) for its drug bitopertin, citing the need for additional data. Levi & Korsinsky, LLP is investigating whether the company adequately disclosed risks associated with the program. The CRL implies a delayed timeline for bitopertin's approval and raises concerns about potential future capital raises that could dilute existing shareholders.
Disc Medicine, Inc. (IRON) Under Investigation for Potential Securities Law Violations - Contact Levi & Korsinsky Today
Levi & Korsinsky has launched an investigation into Disc Medicine, Inc. (NASDAQ: IRON) following a significant decline in its stock price. This comes after the FDA issued a Complete Response Letter for bitopertin, the company's lead therapeutic candidate, delaying its potential approval until at least 2027. The investigation will focus on whether Disc Medicine and its executives adequately disclosed the risks and challenges regarding the drug's regulatory prospects to investors.
IRON Investors Have Opportunity to Join Disc Medicine, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Disc Medicine, Inc. (NASDAQ: IRON) after a Reuters report indicated a delay in the review of its experimental drug due to FDA-raised safety and efficacy concerns. This news led to a more than 7.8% drop in Disc's share price. The firm is encouraging shareholders who experienced losses to contact them to discuss their legal rights.
IRON Investors Have Opportunity to Join Disc Medicine, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Disc Medicine, Inc. (NASDAQ: IRON) for potential securities law violations after a Reuters report indicated a delay in the review of its experimental drug due to FDA safety and efficacy concerns. This news caused Disc's shares to fall by over 7.8%. Investors who suffered losses are encouraged to contact the firm for a fraud investigation.
IRON Drops Up to 39% After FDA CRL for Bitopertin -- LEVI & KORSINSKY, LLP Investigates
Levi & Korsinsky, LLP is investigating Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter (CRL) for its bitopertin drug, causing a significant share price drop. The CRL indicates a need for additional data to approve bitopertin for erythropoietic protoporphyria (EPP), which will delay its market entry and may necessitate further capital raises. Shareholders who suffered losses are encouraged to contact the firm to understand their legal options.
IRON Investors Have Opportunity to Join Disc Medicine, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Disc Medicine, Inc. (NASDAQ: IRON) after a Reuters report indicated a delay in its experimental drug's review due to safety and efficacy concerns flagged by the FDA. This news led to a more than 7.8% drop in Disc's share price. The firm is encouraging investors who suffered losses to participate in their fraud investigation.
Disc Medicine, Inc. (NASDAQ:IRON) Sees Large Growth in Short Interest
Disc Medicine, Inc. (NASDAQ:IRON) experienced a 25.1% increase in short interest during February, reaching 4,269,919 shares, which signals elevated bearish sentiment for the stock. Despite this, analysts maintain a "Moderate Buy" rating with a consensus price target of $104.80, significantly above its current trading price of $60.04. Over the last quarter, insiders sold 206,985 shares worth $17.5M, reducing insider ownership, while institutional investors hold 83.7% of the company's stock.
Checkpoint Capital L.P. Acquires 165,000 Shares of Disc Medicine, Inc. $IRON
Checkpoint Capital L.P. significantly increased its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 62.3% in the third quarter, purchasing an additional 165,000 shares to bring its total holdings to 430,000 shares worth $28.414 million. This move makes Disc Medicine its fourth-largest holding, representing 9.5% of the fund's portfolio. Institutional ownership of Disc Medicine is high at 83.70%, with other notable investments from firms like TimesSquare Capital and JPMorgan Chase & Co., while insiders have recently sold a combined 206,985 shares.
IRON Investors Have Opportunity to Join Disc Medicine, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Disc Medicine, Inc. (NASDAQ: IRON) for alleged securities law violations after a Reuters report indicated a delay in the review of its experimental drug due to FDA concerns regarding safety and efficacy. Following this news, Disc's shares dropped over 7.8%. The firm is inviting investors who suffered losses to participate in the fraud investigation.
